戻る Agenda
Session 2: Mainstreaming Artificial Intelligence (AI) and Machine Learning (ML) in Pharmaceutical Development: How Can We Next-Level AI and ML?
Session Chair(s)
Rebecca Taha, PhD, MBA
Director Biostatistical Consulting
ICON Biotech Solutions, United States
Though the terms Artificial Intelligence (AI) and Machine Learning (ML) are widely used, major scientific advancements in the life sciences are attributable to the technologies that are still in their infancy relative to their potential. This session moves beyond the hype with industry innovators who share their deep experience and technology expertise through real-world examples. From exciting areas of opportunity in clinical development to potentially costly, under-considered problem areas, attendees can expect to broaden their knowledge in this exciting area of transformational technology.
Learning Objective : At the conclusion of this session, participants should be able to:- Discuss potential errors that can result from a narrow understanding of the data feeding into AI/ML algorithms
- Describe the growing areas of opportunity in AI/ML in clinical development, beyond drug discovery
Speaker(s)
Speaker
Representative Invited
Eli Lilly and Company, United States
Speaker
Miruna Sasu, PhD, MBA
COTA, United States
President and Chief Executive Officer